Background: To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man. To determine the optimal dosage and the toxicities of these two agents for future trials.
Introduction
The taxanes represent a relatively new class of antitumor agents which have a broad spectrum of action in human malignancies [1] . These agents are of interest because of their relative paucity of cardiac toxic effects, their unique mode of action, and high levels of preclinical and clinical activity [2, 3] . Hence, they are potentially of interest in oncologic diseases which affect older individuals. In tissue culture, docetaxel is more active than paclitaxel in established prostate cell lines and shows synergism with estramustine, an established agent in this disease [4] . Similar findings have been reported for the combination of estramustine phosphate and paclitaxel [5] . Estamustine has been shown to affect the disassembly of microtubules [6] , is associated only with low levels of resistance in cell lines, and is non-cross resistant with many taxane resistant cell lines [7, 8] , although some cross resistance with paclitaxel has been reported by one investigator [9] . In addition, metabolites of estramustine also bind to the wild-type and mutated androgen receptor as another mode of action [10] . Hence, there are ample preclinical data to suggest that the combination of docetaxel and estramustine should be evaluated in patients with hormone refractory prostate cancer. As these two agents might be expected to have a pharmacodynamic interaction, we decided to hold the estramustine phosphate daily dose static and evaluate dose escalation of docetaxel given on a one every three-week schedule.
Patients and methods
Patients with known hormone refractory prostate cancer who were nol previously exposed to either a taxane or estramustine phosphate, had been exposed to two chemotherapy regimens or fewer, recovered from past toxicities, with a South West Oncology Group (SWOG) performance status [11] < 2 as ambulatory out patients, with normal renal function (serum creatinine $1.4 mg/dl), hepatic function (bilirubin and transaminases within laboratory normal values), and an absolute neutrophil count > 1500/ul and platelet count >100,000/ul were offered the study. All protocol patients signed informed, written consent as per Institutional and the Federal Food and Drug Administration guidelines. Patients were declared endocrine treatment failures on the basis of having achieved castrate levels of serum testosterone on their hormonal treatment and progression of metastatic disease as previously denned [12, 13] . Patients were restaged with imaging (chest X-ray, bone scan, and CAT scan), EKG, chemistries, prostate specific antigen (PSA), urine analysis, and physical examinations prior to start of study. During the study, weekly blood counts, glucose, BUN, creatinine, liver function tests, electrolytes, and toxicity scores were obtained. Patients were formally examined every three weeks and imaging studies were repeated starting nine weeks after entry at intervals of every six weeks when previous sites of disease were identified or new complaints developed. Serum PSA levels were obtained every three weeks. In the case of a 50% change in level of PSA, the test was repeated within two weeks to verify response or progression as previously described [12, 14] . Responses were graded according to standard criteria [12, 13, 15, 16] . All responses had to endure for a minimum of four weeks. In brief, a complete response was defined as the disappearance of all clinical evidence of malignancy by physical examination, imaging studies, and/or by normalization of the PSA on two consecutive occasions at least two weeks apart for nonmeasurable disease. Complete PSA response was denned as a plasma PSA < 4 ng/ml lasting greater than one month. Partial response was defined as a 50% or greater decrease in the sum of the above parameters or a PSA decline by greater than 50% from baseline measured twice at least two weeks apart [12] . Duration of response was scored from initial determination of shrinkage on measurement until evidence of progression or, if by PSA, from initial biochemical response until return to baseline value. Toxicities were scored according to North American Cooperative Group criteria [11] . All patients receiving one cycle to therapy were considered evaluable for toxicity. A maximum of six cycles were administered to prevent the edema syndrome seen with chronic docetaxel administration. Dose limiting toxicity (DLT) was defined as the appearance of any grade 4 toxicity. Maximal tolerated dose (MTD) was defined as that dose level in which in one third of the patients had DLT. Suggested phase II dosing level was defined as one dose below MTD and in addition the dose level which also displayed reversible toxicity on repetitive treatments. A minimum of three patients were entered into each study dose level cohort. No patient was dose escalated from one cohort to another. In the case of DLT in one-third of patients, additional patients were entered at one dose level below this MTD. In the case of uncertainty about etiology of toxicity, additional patients were entered on a given dose level. Dose intensities of the two drugs administered over the number of cycles delivered were determined by dividing the actually delivered dose in mg/m 2 per unit time (in the case of estramustine phosphate as mg/kg per unit time) by the protocol mandated dosing in mg/m 2 per unit time. previously evaluated with some efficacy demonstrated [18] , and the duration of treatment time with estramustine to potentially result in a synergistic effect with intermittent docetaxel was unknown, the estramustine phosphate was held at a static daily dose which was previously believed to be tolerable in this patient population [18] . Estramustine phosphate was administered orally daily divided into three doses with a total daily dose of 14 mg/kg. The cycle length was 21 days. The total dose in milligrams was rounded off to the nearest intact tablet. The drug was ingested with water at least one-half hour prior to meals or two hours after eating. In the presence of grade 2 or more nausea or diarrhea from the estramustine phosphate, patients were taken off the medication until the toxicity resolved. The estramustine phosphate was then reintroduced by first giving a reduced dose and escalating daily to a tolerated dosage. Docetaxel, starting concurrently, was diluted in 5% dextrose to a final concentration between 0.3 and 0.9 mg/ml and then administered intravenously over one hour. Anticmetics were standardized to granisetron 10 ug/kg i.v. prior to chemotherapy. Dexamethasone 8 mg by mouth twice a day was administered starting 24 hours prior to docetaxel and continued for a total of five days to prevent fluid accumulation [19, 20] . As the tolerable dose range for treatment in man with docetaxel was already known [21] , the dose escalation scheme used for docetaxel was conservative: 40 (level 1), 60 (level 2), 70 (level 3), and 80 (level 4) mg/m 2 with retreatment every 21 days. The 70 mg/m 2 dose level was added to the dose finding schema after rapid escalation to 80 mg/m 2 was determined to be intolerable.
Treatment plan
Estramustine phosphate 140 mg tablets were obtained from commercial sources. Docetaxel was provided as 20 and 80 mg vials by RhonePoulenc Rorer (Collegeville, PA). Three patients had received an orchiectomy and therefore were not on LH/RH agonist suppression. They had previously received an antiandrogen and failed to respond. One patient had refused either an orchiectomy or an LH/RH agonist and was initially treated with an antiandrogen alone with documented progression before entry onto the study. All other patients were maintained on an LH/RH agonist. All study patients except the already described one patient only on an antiandrogen were off antiandrogens for a minimum of four weeks to preclude a withdrawal response confusing evaluation of the present treatment [12. 17] . As chronic daily dosing with estramustine phosphate in this patient population was
Results
A total of 17 patients with PS of 0-1 and one patient with PS 2 were entered onto this study with a mean age of 66 years (Table 1) . Prior cytotoxic therapy consisted of cyclophosphamide in one patient. Twelve patients had received prior radiation therapy; 10 patients having prior pelvic radiation for initial treatment of the disease and two patients having prior radiation therapy for symptomatic relief of bone pain. Six patients had soft tissue measurable disease. Serum PSA for the group was a Despite administration of the recommended dose and schedule of estramustine phosphate, these patients initially tolerated this drug poorly with the immediate development of grade 1-2 nausea and vomiting at all dose levels of docetaxel. Diarrhea grades 1-3 was seen in 10 of the 17 patients at all dose levels with one patient reaching grade 3 at dose level 4. No cumulative effect of nausea or diarrhea was observed. As these toxicities have been previously attributed to estramustine, this drug was temporally withheld and then restarted as previously described in Methods. This approach allowed significant actual drug delivery when compared to the protocol mandated theoretical dosage. As a result, the actual dose intensity of estramustine phosphate (defined as delivered dose per day divided by the protocol targeted 100% dosage) was for level 1: 96%, for level 2: 93%, for level 3: 96% and for level 4: 80% (Table 2 ). For the group as a whole, 87% of the dose intensity of EP could be delivered (Table 2) . Dose intensity of docetaxel on this treatment program was for level 1: 100%, for level 2: 99%, for level 3: 88% and for level 4: 96%. No cumulative toxicity was noted in the patients who received multiple cycles of treatment.
Alopecia was seen at all dose levels. The delayed effect of fluid retention was seen in the finding of pedal edema. The edema was not dose limiting (grade 1-2). The hematologic toxicity of this combination is illustrated in Table 3 . Dose related neutropenia was noted as the docetaxel dosage was increased and was evident after the first cycle of treatment. Dose level 1 was associated with mild anemia and no significant leukopenia or thrombocytopenia. Neutropenia was noted at level 2 with absolute values 700-800/ul, at level 3: 3OO-70O/ul, and at level 4: 0-500/ul. The significant neutropenia persisted for approximately one week. Neutropenia was apparent during the first cycle of therapy. All hematologic toxicity was reversible. Dose level 3 (six patients entered) was associated with grade 4 neutropenia in two patients (Table 3) . In contrast to level 4, repetitive dosing was possible with docetaxel at 70 mg/m 2 in all six patients treated at this dose level (Table 3 ). Grade 2 anemia was seen only in two patients: one at the lowest dose level, and the other at the highest dose level of docetaxel. No thrombocytopenia was seen.
Because of the paucity of hematologic side effects noted at level 2, the study initially escalated the docetaxel dose to 80 mg/m 2 (level 4) and saw the appearance of grade 4 neutropenia in two of three patients (Table 3) associated with unacceptable nonhematological toxicities: gastrointestinal toxicity manifested as diarrhea and abdominal pain combined with neutropenia led to hospitalization in one patient. These toxicities were evident at the first cycle of treatment. At this dose level (level 4) fatigue also became DLTwith grades 3-4 seen in two out of three patients treated in this cohort. As a result, only one patient out of the three received more than one cycle of treatment with docetaxel at 80 mg/m 2 (Table 4) . However, at level 3 two vascular events occurred. In one patient, an arterial embolus, possibly related to therapy, developed during the treatment (Table 4) . No preexisting medical condition (except for smoking) could explain the thrombosis, and an extensive search for an etiology did not result in an answer. An additional patient at this dose level with no past history of coagulation abnormalities suffered a deep venous thrombosis of the lower extremity. Both patients recovered after Fatigue of lesser significance was also observed at all dose levels. A significant skin rash (grade 2) in one patient at level 4 presenting as diffuse, painful erythema rapidly resolved after discontinuance of treatment. Edema, a potential side effect of both docetaxel and estramustine phosphate, was not seen to exceed grade 2.
Laboratory abnormalities were also noted, including non-symptomatic hypoalbuminemia, low plasma total protein, hypophosphatemia, hypocalcemia (grade 2 or less), hyponatremia, and elevated transaminases. In the case of the hypophosphatemia, this abnormality occurred at all dose levels and usually appeared between one and three weeks of combined therapy. Reversible elevations of serum liver transaminase (AST and ALT) were also noted to reach grade 3 at one week post initiation of treatment in one patient each at dose levels 3 and 4.
Responses were seen in this small cohort of patients although this was not the primary endpoint of the study. One patient at DLT level 4 had resolution of lung metastases and disappearance of one of two liver lesions. None of the other five patients with soft tissue disease had evidence of a major response by repeat imaging studies. Eighty-two percent of patients (14 out of 17) had transient biochemical responses as measured by greater than a 50% decline of PSA lasting between 1 and 11 + months. At dose level 1, 4 of 5 patients demonstrated a decline in PSA greater than 50% with patient one achieving a 99% reduction from the baseline value six weeks after treatment. In this small cohort of patients, PSA responses seemed to be dose related with the majority of responses seen at dose levels 3 and 4. At dose level 4, one patient (the only one to tolerate more than one cycle of treatment at that level) achieved a complete normalization of PSA lasting 11+ months despite discontinuing therapy after six cycles (Table 4 , patient 10). At the suggested phase II dose (level 3), 2 of 6 patients had normalization of their PSA (lasting five weeks and 6.5 months) with two additional patients demonstrating significant improvement of greater than 75% reduction from the baseline value.
Reasons for termination of protocol treatment are shown on Table 4 . The majority of patients receiving treatment dosages below DLT were withdrawn for progressive disease with 1 to 12 cycles of treatment administered. At the suggested phase II dosage, an average of five cycles were administered (range 2-9). Patients at DLT withdrew from further treatment either as a result of their grade 4 hematological toxicity or grade 3 fatigue.
Discussion
Evaluation of new agents and combination therapies in metastatic prostate cancer has been clouded by the lack of easily measurable disease, the common presentation of elderly patients with comorbid conditions, and the lack of agreement on the value of biochemical parameters to assess response [22] . In an attempt to enhance the relatively minor antitumor effects of existing agents in this disease, investigators have combined estramustine phosphate with vinblastine, etoposide, paclitaxel, and, more recently, docetaxel [14, [23] [24] [25] , The majority of these studies used continuous daily dosing of estramustine phosphate. We therefore based our clinical study on the synergism seen in a preclinical model [4] , the known toxicity profile of estramustine phosphate with the ability to dose this agent daily [18] , and the well known non-overlapping toxicities, except for edema, of docetaxel [21] .
Administration of daily oral estramustine phosphate with intravenous docetaxel every 21 days was associated with nausea, vomiting, diarrhea, and abdominal pain which led to these patients actually receiving a chronic daily dosage of 12 mg/kg of estramustine phosphate (87% ± 11% of projected dose intensity) because of dose adjustments to patient tolerance. Dose limiting side effects occurred with the combination when docetaxel was administered at 80 mg/m 2 manifested as neutropenia, severe diarrhea, and fatigue. These effects are not totally unexpected in light of the known toxicities of docetaxel [21, 26] . Significant edema was not observed in this patient population despite the use of both drugs. Biochemical abnormalities such as transaminitis, hypocalcemia, hyponatremia, and hypophosphatemia were also noted in this study. Transaminitis has been previously noted with docetaxel [21, 27] as well as with estramustine [18] , but the electrolyte abnormalities, although not clinically apparent, were unexpected. Two vascular events occurred at the suggested phase II dose level (docetaxel 70 mg/m 2 ) and may have been related to the therapy. Thromboembolic events have been previously seen with estamustine [18] and the absence of recurrent thromboembolic events in these two patients after discontinuing this therapy suggests a causative relationship.
This study used a significant course of high-dose dexamethasone given over five days based upon emerging information on methods to reduce docetaxel toxicity. No hypersensitivity reactions were noted in this study. Perhaps of interest, in the preclinical model using human prostate cancer cell lines, high dose dexamethasone markedly potentiates the cytotoxic effects of docetaxel [4] . This effect was not identified in a B16 melanoma model [28] , and therefore may be cell-line specific. However, we can not discern in the present clinical study whether or not the use of corticosteroids was in part responsible for the antitumor effects seen. In addition, the use of low dose dexamethasone by itself for the treatment of prostate cancer has been reported to produce clinical symptomatic improvement and reduction of PSA in 34% of treated patients [29] .
Responses, denned as a statistically significant reduction in baseline PSA, were noted with normalization of PSA in 24% of patients treated in this small cohort of patients. Eighty-two percent of the study patients had greater than a 50% drop in PSA lasting from 1 to 11 + months. Some previous studies have suggested a survival advantage in such patients [12, 15, 30, 31] . Hence, a larger study of this combination may be warranted to evaluate the effect of this combination of agents on both PSA and survival. One patient with soft tissue disease, in addition to bony disease, had a partial response on imaging studies (17% of measurable disease patients).
Another study has also pursued this combination with preliminary results now available. These investigators allowed prior treatment with estamustine, gave a fiveday schedule of oral estamustine phosphate, and an abbreviated dose of dexamethasone. In a small group of patients, their results were similar with a high response rate measured by-reduction of circulating PSA, and treatment was associated with similar toxicities [24] .
Based upon our present study, we believe that further evaluation of the combination of estramustine phosphate and docetaxel is warranted. The role of concomitant corticosteroids also needs to be defined. Suggested phase II dosages of this combination which can be maintained in this patient population based upon our described trial are 12 mg/kg estramustine phosphate daily with 70 mg/m 2 of docetaxel administered every 21 days.
